Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

103 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabrafenib plus trametinib is effective in the treatment of BRAF V600-mutated metastatic melanoma patients: analysis of patients from the dabrafenib plus trametinib Named Patient Program (DESCRIBE II).
Atkinson V, Sandhu S, Hospers G, Long GV, Aglietta M, Ferrucci PF, Tulyte S, Cappellini GCA, Soriano V, Ali S, Poprach A, Cesas A, Rodriguez-Abreu D, Lau M, de Jong E, Legenne P, Stein D, King B, van Thienen JV. Atkinson V, et al. Among authors: poprach a. Melanoma Res. 2020 Jun;30(3):261-267. doi: 10.1097/CMR.0000000000000654. Melanoma Res. 2020. PMID: 31895752
Comparison of Two Prognostic Models in Patients with Metastatic Renal Cancer Treated with Sunitinib: a Retrospective, Registry-Based Study.
Kubackova K, Melichar B, Bortlicek Z, Pavlik T, Poprach A, Svoboda M, Lakomy R, Vyzula R, Kiss I, Dusek L, Prausova J, Buchler T; Czech Renal Cancer Cooperative Group. Kubackova K, et al. Among authors: poprach a. Target Oncol. 2015 Dec;10(4):557-63. doi: 10.1007/s11523-015-0366-9. Target Oncol. 2015. PMID: 25903462
Efficacy and Toxicity of Panitumumab After Progression on Cetuximab and Predictive Value of MiR-31-5p in Metastatic Wild-type KRAS Colorectal Cancer Patients.
Kiss I, Mlcochova J, Bortlicek Z, Poprach A, Drabek J, Vychytilova-Faltejskova P, Svoboda M, Buchler T, Batko S, Ryska A, Hajduch M, Slaby O. Kiss I, et al. Among authors: poprach a. Anticancer Res. 2016 Sep;36(9):4955-9. doi: 10.21873/anticanres.11063. Anticancer Res. 2016. PMID: 27630355 Clinical Trial.
Utilization and efficacy of second-line targeted therapy in metastatic renal cell carcinoma: data from a national registry.
Lakomy R, Poprach A, Bortlicek Z, Melichar B, Chloupkova R, Vyzula R, Zemanova M, Kopeckova K, Svoboda M, Slaby O, Kiss I, Studentova H, Juracek J, Fiala O, Kopecky J, Finek J, Dusek L, Hejduk K, Buchler T. Lakomy R, et al. Among authors: poprach a. BMC Cancer. 2017 Dec 21;17(1):880. doi: 10.1186/s12885-017-3901-5. BMC Cancer. 2017. PMID: 29268716 Free PMC article.
103 results